Aclaris Therapeutics Inc. (ACRS) Fundamentals

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
SHARE INFORMATION
Market Cap$ 1,120,085,400
Shares Outstanding66,671,750
Float64,264,064
Percent Float96.39%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 6,761,000
Latest Fiscal EPS$ -1.63
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions286
Institutional Holdings Date2022-07-31
Institutional Bought Previous 3 Months8,821,731
Institutional Holdings Percent112.8%
Institutional Sold Previous 3 Months7,485,610
Insider Holdings Date2022-07-31
Insider Bought Previous 3 Months458,904
Insider Holdings Percent4.2
Insider Sold Previous 3 Months47,122
Insider Shares Owned2,589,088
TRADING INFO
52 Week High$ 19.97
52 Week Low$ 9.26
52 Week High Change$ 14.29
21 Day Moving Average$ 15.8424
21 Day Extended Moving Average$ 16.048
50 Day Moving Average$ 15.3196
50 Day Extended Moving Average$ 15.3541
200 Day Moving Average$ 14.2638
200 Day Extended Moving Average$ 14.79
10 Day Average Volume344,001
20 Day Average Volume276,950
30 Day Average Volume271,896
50 Day Average Volume358,850
Alpha0.026439
Beta0.6185
Standard Deviation0.369534
R20.007008
7 Day Price Change$ 0.03
7 Day Percent Change0.18%
21 Day Price Change$ 0.90
21 Day Percent Change5.66%
30 Day Price Change$ 1.31
30 Day Percent Change8.46%
Month to Date Price Change$ 1.39
Month to Date Percent Change9.02%
Quarter to Date Price Change$ 2.84
Quarter to Date Percent Change20.34%
180 Day Price Change$ 4.09
180 Day Percent Change32.18%
200 Day Price Change$ 7.06
200 Day Percent Change72.48%
Year to Date Price Change$ 2.26
Year to Date Percent Change15.54%

Aclaris Therapeutics Inc. (ACRS) Key Ratios

PROFITABILITY
EBIT Margin-1,377.4%
EBITDA Margin-1,364.4%
Pre-Tax Profit Margin-2,098.6%
Profit Margin Count0.0%
Gross Margin12.8%
Profit Margin TOT0.0%
INCOME STATEMENTS
Revenue$ 6,141,000
Revenue Per Share$ 0.0921
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book4.90
Total Debt To Equity0.00
Int Coverage0.00
Current Ratio16.00
Leverage Ratio1.20
Quick Ratio15.40
Long Term Debt To Capital0.04
VALUATION MEASURES
PE Ratio-12.60
Enterprise Value$ 878,890,575
Price to Sales182.3946
Price to Free Cash-16.30
PE High Last 5 Years-2.00
Price To Book4.80
Price To Cash Flow0.00
PE Low Last 5 Years-9.40
Price to Tangible Book4.90
MANAGEMENT EFFECTIVENESS
Receivables Turnover9.00
Invoice Turnover0.00
Assets Turnover0.00
Return Assets-31.27
Return on Equity-37.65
Return on Capital-35.36

Aclaris Therapeutics Inc. (ACRS) Profile

PROFILE INFO
Issue TypeCS
SEC TypeEQS
AuditorPricewaterhouseCoopers LLP
CEONeal Walker
Emplyoees77
Last AuditUQ
CIK0001557746
IndustryMedical Diagnostics & Research
SectorHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)(541714)
CONTACT INFO
Address640 Lee Road
Suite 200
Wayne, PA 19087
Websitehttps://www.aclaristx.com
Facsimile+1 484 320-2344
Telephone+1 484 324-7933
Emailmtung@aclaristx.com


Your Recent History
NASDAQ
ACRS
Aclaris Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.